Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
- PMID: 20017892
- PMCID: PMC2808730
- DOI: 10.1186/gm114
Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
Abstract
The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions.
References
-
- Brenner S. My Life in Science. London: BioMed Central; 2001.
-
- Johnson FL, Thomas ED. Treatment of relapsed acute lymphoblastic leukemia in childhood. N Engl J Med. 1984;310:263. - PubMed
-
- Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306:645–652. - PubMed
-
- Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306:712–718. - PubMed
LinkOut - more resources
Full Text Sources
